Taimei regularly audits the system services through independent third-party on SOC2 standards. The SOC2 audit report meets the Trusted Service Principles (TSP Section 100) proposed by the American Institute of Certified Public Accountants (AICPA). Taimei has designed and implemented a complete internal control system, and security & privacy management processes and technologies, including data security and key management, security vulnerabilities, security incidents and fault management, terminal management, availability management, privacy protection and among others. In addition to the traditionally focused security, availability and confidentiality, data privacy has gradually become a major factor of the evaluation. Taimei has passed the audits in the four areas of security, availability, confidentiality and privacy, which means that Taimei has the ability to provide reliable security & privacy protection and services for global customers. Any distribution of the report requires an application to Taimei and the report shall be only shared under a non-disclosure agreement.
Taimei has passed the internationally recognized business continuity management system certification, which strongly demonstrates Taimei’s ability to respond to emergencies. The ISO 22301 business continuity management system standard provides international best practices that help Taimei respond and recover effectively from disruptions. This certification helps Taimei, as a SAAS operating platform provider, have sufficient flexibility to respond to different events and establish the dependability and sustainable development of enterprise operations.
The TRUSTe Certification is issued by TrustArc, a prominent US privacy certification organization and the preferred choice for most Chinese companies expanding internationally. The privacy framework of the report is structured based on recognized legal standards (e.g., GDPR, HIPAA, etc.). This certification serves as compelling evidence of an enterprise’s privacy compliance capabilities in the biopharmaceutical industry.